Therapeutic alliance and glycaemic control in type 1 diabetes: a pilot study.
Identifieur interne : 001816 ( Main/Exploration ); précédent : 001815; suivant : 001817Therapeutic alliance and glycaemic control in type 1 diabetes: a pilot study.
Auteurs : C. Attale [France] ; C. Lemogne ; A. Sola-Gazagnes ; N. Guedeney ; G. Slama ; A-O Horvath ; S-M ConsoliSource :
- Diabetes & metabolism [ 1878-1780 ] ; 2010.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Complications du diabète (prévention et contrôle), Complications du diabète (épidémiologie), Diabète de type 1 (complications), Diabète de type 1 (psychologie), Diabète de type 1 (sang), Diabète de type 1 (thérapie), Dépression (complications), Dépression (prévention et contrôle), Dépression (épidémiologie), Enquêtes et questionnaires (MeSH), Femelle (MeSH), France (épidémiologie), Humains (MeSH), Hémoglobine A glycosylée (analyse), Hôpitaux universitaires (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Médecins (MeSH), Projets pilotes (MeSH), Relations médecin-patient (MeSH), Rétinopathie diabétique (prévention et contrôle), Rétinopathie diabétique (épidémiologie), Soins centrés sur le patient (MeSH), Échelles d'évaluation en psychiatrie (MeSH), Études longitudinales (MeSH).
- MESH :
- analyse : Hémoglobine A glycosylée.
- prévention et contrôle : Complications du diabète, Dépression, Rétinopathie diabétique.
- psychologie : Diabète de type 1.
- sang : Diabète de type 1, Dépression.
- thérapie : Diabète de type 1.
- épidémiologie : Complications du diabète, Dépression, France, Rétinopathie diabétique.
- Adulte, Adulte d'âge moyen, Enquêtes et questionnaires, Femelle, Humains, Hôpitaux universitaires, Jeune adulte, Mâle, Médecins, Projets pilotes, Relations médecin-patient, Soins centrés sur le patient, Échelles d'évaluation en psychiatrie, Études longitudinales.
English descriptors
- KwdEn :
- Adult (MeSH), Depression (complications), Depression (epidemiology), Depression (prevention & control), Diabetes Complications (epidemiology), Diabetes Complications (prevention & control), Diabetes Mellitus, Type 1 (blood), Diabetes Mellitus, Type 1 (complications), Diabetes Mellitus, Type 1 (psychology), Diabetes Mellitus, Type 1 (therapy), Diabetic Retinopathy (epidemiology), Diabetic Retinopathy (prevention & control), Female (MeSH), France (epidemiology), Glycated Hemoglobin A (analysis), Hospitals, University (MeSH), Humans (MeSH), Longitudinal Studies (MeSH), Male (MeSH), Middle Aged (MeSH), Patient-Centered Care (MeSH), Physician-Patient Relations (MeSH), Physicians (MeSH), Pilot Projects (MeSH), Psychiatric Status Rating Scales (MeSH), Surveys and Questionnaires (MeSH), Young Adult (MeSH).
- MESH :
- chemical , analysis : Glycated Hemoglobin A.
- blood : Diabetes Mellitus, Type 1.
- complications : Depression, Diabetes Mellitus, Type 1.
- epidemiology : Depression, Diabetes Complications, Diabetic Retinopathy, France.
- prevention & control : Depression, Diabetes Complications, Diabetic Retinopathy.
- psychology : Diabetes Mellitus, Type 1.
- therapy : Diabetes Mellitus, Type 1.
- Adult, Female, Hospitals, University, Humans, Longitudinal Studies, Male, Middle Aged, Patient-Centered Care, Physician-Patient Relations, Physicians, Pilot Projects, Psychiatric Status Rating Scales, Surveys and Questionnaires, Young Adult.
Abstract
AIM
Effective diabetes care requires integrating physicians' clinical expertise with patients' concerns and resources. This prospective study examined whether or not two measures of therapeutic alliance could predict glycaemic control after 1 year of follow-up in patients with type 1 diabetes.
METHODS
Consecutive type 1 diabetic outpatients were recruited, and their age, gender, level of education, marital status and age at the time of diabetes diagnosis were self-reported. The presence of diabetes complications was ascertained by the patients' physicians. Both patients and physicians completed the revised Helping Alliance Questionnaire (HAQ-R) and the 12-item Working Alliance Inventory (WAI-12) to assess therapeutic alliance. Patients also completed the Center for Epidemiological Studies Depression scale to assess depressive mood. HbA(1c) was measured at baseline and 1 year later.
RESULTS
Sixty-four type 1 diabetic outpatients (32 men, 32 women; mean age±standard deviation [S.D.]: 38.2±8.0 years) were included. HbA(1c) level at follow-up (mean±S.D.: 7.56±1.18%) was positively correlated with the HbA(1c) level at baseline (r=0.698, P<0.001), and associated with presence of retinopathy at baseline (8.18±1.24% versus 7.41±1.13%, P=0.036). In addition, the HbA(1c) level at follow-up was negatively correlated with therapeutic alliance, as assessed at baseline by the physicians using either the HAQ-R (r=-0.431, P<0.001) or the WAI-12 (r=-0.365, P=0.003), even after controlling for the HbA(1c) at baseline.
CONCLUSION
Although the observational nature of the present study prevents causal conclusions to be drawn, these preliminary results suggest that promoting therapeutic alliance can improve glycaemic control in type 1 diabetes.
DOI: 10.1016/j.diabet.2010.08.003
PubMed: 20934364
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic alliance and glycaemic control in type 1 diabetes: a pilot study.</title><author><name sortKey="Attale, C" sort="Attale, C" uniqKey="Attale C" first="C" last="Attale">C. Attale</name><affiliation wicri:level="3"><nlm:affiliation>Paris Descartes University, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Paris Descartes University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lemogne, C" sort="Lemogne, C" uniqKey="Lemogne C" first="C" last="Lemogne">C. Lemogne</name></author><author><name sortKey="Sola Gazagnes, A" sort="Sola Gazagnes, A" uniqKey="Sola Gazagnes A" first="A" last="Sola-Gazagnes">A. Sola-Gazagnes</name></author><author><name sortKey="Guedeney, N" sort="Guedeney, N" uniqKey="Guedeney N" first="N" last="Guedeney">N. Guedeney</name></author><author><name sortKey="Slama, G" sort="Slama, G" uniqKey="Slama G" first="G" last="Slama">G. Slama</name></author><author><name sortKey="Horvath, A O" sort="Horvath, A O" uniqKey="Horvath A" first="A-O" last="Horvath">A-O Horvath</name></author><author><name sortKey="Consoli, S M" sort="Consoli, S M" uniqKey="Consoli S" first="S-M" last="Consoli">S-M Consoli</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20934364</idno><idno type="pmid">20934364</idno><idno type="doi">10.1016/j.diabet.2010.08.003</idno><idno type="wicri:Area/Main/Corpus">001775</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001775</idno><idno type="wicri:Area/Main/Curation">001775</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001775</idno><idno type="wicri:Area/Main/Exploration">001775</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic alliance and glycaemic control in type 1 diabetes: a pilot study.</title><author><name sortKey="Attale, C" sort="Attale, C" uniqKey="Attale C" first="C" last="Attale">C. Attale</name><affiliation wicri:level="3"><nlm:affiliation>Paris Descartes University, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Paris Descartes University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lemogne, C" sort="Lemogne, C" uniqKey="Lemogne C" first="C" last="Lemogne">C. Lemogne</name></author><author><name sortKey="Sola Gazagnes, A" sort="Sola Gazagnes, A" uniqKey="Sola Gazagnes A" first="A" last="Sola-Gazagnes">A. Sola-Gazagnes</name></author><author><name sortKey="Guedeney, N" sort="Guedeney, N" uniqKey="Guedeney N" first="N" last="Guedeney">N. Guedeney</name></author><author><name sortKey="Slama, G" sort="Slama, G" uniqKey="Slama G" first="G" last="Slama">G. Slama</name></author><author><name sortKey="Horvath, A O" sort="Horvath, A O" uniqKey="Horvath A" first="A-O" last="Horvath">A-O Horvath</name></author><author><name sortKey="Consoli, S M" sort="Consoli, S M" uniqKey="Consoli S" first="S-M" last="Consoli">S-M Consoli</name></author></analytic><series><title level="j">Diabetes & metabolism</title><idno type="eISSN">1878-1780</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Depression (complications)</term><term>Depression (epidemiology)</term><term>Depression (prevention & control)</term><term>Diabetes Complications (epidemiology)</term><term>Diabetes Complications (prevention & control)</term><term>Diabetes Mellitus, Type 1 (blood)</term><term>Diabetes Mellitus, Type 1 (complications)</term><term>Diabetes Mellitus, Type 1 (psychology)</term><term>Diabetes Mellitus, Type 1 (therapy)</term><term>Diabetic Retinopathy (epidemiology)</term><term>Diabetic Retinopathy (prevention & control)</term><term>Female (MeSH)</term><term>France (epidemiology)</term><term>Glycated Hemoglobin A (analysis)</term><term>Hospitals, University (MeSH)</term><term>Humans (MeSH)</term><term>Longitudinal Studies (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Patient-Centered Care (MeSH)</term><term>Physician-Patient Relations (MeSH)</term><term>Physicians (MeSH)</term><term>Pilot Projects (MeSH)</term><term>Psychiatric Status Rating Scales (MeSH)</term><term>Surveys and Questionnaires (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Complications du diabète (prévention et contrôle)</term><term>Complications du diabète (épidémiologie)</term><term>Diabète de type 1 (complications)</term><term>Diabète de type 1 (psychologie)</term><term>Diabète de type 1 (sang)</term><term>Diabète de type 1 (thérapie)</term><term>Dépression (complications)</term><term>Dépression (prévention et contrôle)</term><term>Dépression (épidémiologie)</term><term>Enquêtes et questionnaires (MeSH)</term><term>Femelle (MeSH)</term><term>France (épidémiologie)</term><term>Humains (MeSH)</term><term>Hémoglobine A glycosylée (analyse)</term><term>Hôpitaux universitaires (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Médecins (MeSH)</term><term>Projets pilotes (MeSH)</term><term>Relations médecin-patient (MeSH)</term><term>Rétinopathie diabétique (prévention et contrôle)</term><term>Rétinopathie diabétique (épidémiologie)</term><term>Soins centrés sur le patient (MeSH)</term><term>Échelles d'évaluation en psychiatrie (MeSH)</term><term>Études longitudinales (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Glycated Hemoglobin A</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Hémoglobine A glycosylée</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Diabetes Mellitus, Type 1</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Depression</term><term>Diabetes Mellitus, Type 1</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Depression</term><term>Diabetes Complications</term><term>Diabetic Retinopathy</term><term>France</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Depression</term><term>Diabetes Complications</term><term>Diabetic Retinopathy</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Complications du diabète</term><term>Dépression</term><term>Rétinopathie diabétique</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Diabète de type 1</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Diabetes Mellitus, Type 1</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Diabète de type 1</term><term>Dépression</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Diabetes Mellitus, Type 1</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Diabète de type 1</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Complications du diabète</term><term>Dépression</term><term>France</term><term>Rétinopathie diabétique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Hospitals, University</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Patient-Centered Care</term><term>Physician-Patient Relations</term><term>Physicians</term><term>Pilot Projects</term><term>Psychiatric Status Rating Scales</term><term>Surveys and Questionnaires</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Humains</term><term>Hôpitaux universitaires</term><term>Jeune adulte</term><term>Mâle</term><term>Médecins</term><term>Projets pilotes</term><term>Relations médecin-patient</term><term>Soins centrés sur le patient</term><term>Échelles d'évaluation en psychiatrie</term><term>Études longitudinales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>AIM</b></p><p>Effective diabetes care requires integrating physicians' clinical expertise with patients' concerns and resources. This prospective study examined whether or not two measures of therapeutic alliance could predict glycaemic control after 1 year of follow-up in patients with type 1 diabetes.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Consecutive type 1 diabetic outpatients were recruited, and their age, gender, level of education, marital status and age at the time of diabetes diagnosis were self-reported. The presence of diabetes complications was ascertained by the patients' physicians. Both patients and physicians completed the revised Helping Alliance Questionnaire (HAQ-R) and the 12-item Working Alliance Inventory (WAI-12) to assess therapeutic alliance. Patients also completed the Center for Epidemiological Studies Depression scale to assess depressive mood. HbA(1c) was measured at baseline and 1 year later.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Sixty-four type 1 diabetic outpatients (32 men, 32 women; mean age±standard deviation [S.D.]: 38.2±8.0 years) were included. HbA(1c) level at follow-up (mean±S.D.: 7.56±1.18%) was positively correlated with the HbA(1c) level at baseline (r=0.698, P<0.001), and associated with presence of retinopathy at baseline (8.18±1.24% versus 7.41±1.13%, P=0.036). In addition, the HbA(1c) level at follow-up was negatively correlated with therapeutic alliance, as assessed at baseline by the physicians using either the HAQ-R (r=-0.431, P<0.001) or the WAI-12 (r=-0.365, P=0.003), even after controlling for the HbA(1c) at baseline.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Although the observational nature of the present study prevents causal conclusions to be drawn, these preliminary results suggest that promoting therapeutic alliance can improve glycaemic control in type 1 diabetes.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20934364</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1780</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>6 Pt 1</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Diabetes & metabolism</Title><ISOAbbreviation>Diabetes Metab</ISOAbbreviation></Journal><ArticleTitle>Therapeutic alliance and glycaemic control in type 1 diabetes: a pilot study.</ArticleTitle><Pagination><MedlinePgn>499-502</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.diabet.2010.08.003</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Effective diabetes care requires integrating physicians' clinical expertise with patients' concerns and resources. This prospective study examined whether or not two measures of therapeutic alliance could predict glycaemic control after 1 year of follow-up in patients with type 1 diabetes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Consecutive type 1 diabetic outpatients were recruited, and their age, gender, level of education, marital status and age at the time of diabetes diagnosis were self-reported. The presence of diabetes complications was ascertained by the patients' physicians. Both patients and physicians completed the revised Helping Alliance Questionnaire (HAQ-R) and the 12-item Working Alliance Inventory (WAI-12) to assess therapeutic alliance. Patients also completed the Center for Epidemiological Studies Depression scale to assess depressive mood. HbA(1c) was measured at baseline and 1 year later.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-four type 1 diabetic outpatients (32 men, 32 women; mean age±standard deviation [S.D.]: 38.2±8.0 years) were included. HbA(1c) level at follow-up (mean±S.D.: 7.56±1.18%) was positively correlated with the HbA(1c) level at baseline (r=0.698, P<0.001), and associated with presence of retinopathy at baseline (8.18±1.24% versus 7.41±1.13%, P=0.036). In addition, the HbA(1c) level at follow-up was negatively correlated with therapeutic alliance, as assessed at baseline by the physicians using either the HAQ-R (r=-0.431, P<0.001) or the WAI-12 (r=-0.365, P=0.003), even after controlling for the HbA(1c) at baseline.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although the observational nature of the present study prevents causal conclusions to be drawn, these preliminary results suggest that promoting therapeutic alliance can improve glycaemic control in type 1 diabetes.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Attale</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Paris Descartes University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemogne</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sola-Gazagnes</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Guedeney</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Slama</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Horvath</LastName><ForeName>A-O</ForeName><Initials>AO</Initials></Author><Author ValidYN="Y"><LastName>Consoli</LastName><ForeName>S-M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Diabetes Metab</MedlineTA><NlmUniqueID>9607599</NlmUniqueID><ISSNLinking>1262-3636</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C517652">hemoglobin A1c protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003930" MajorTopicYN="N">Diabetic Retinopathy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin A</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018802" MajorTopicYN="Y">Patient-Centered Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010817" MajorTopicYN="N">Physician-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010820" MajorTopicYN="N">Physicians</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20934364</ArticleId><ArticleId IdType="pii">S1262-3636(10)00152-7</ArticleId><ArticleId IdType="doi">10.1016/j.diabet.2010.08.003</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Consoli, S M" sort="Consoli, S M" uniqKey="Consoli S" first="S-M" last="Consoli">S-M Consoli</name><name sortKey="Guedeney, N" sort="Guedeney, N" uniqKey="Guedeney N" first="N" last="Guedeney">N. Guedeney</name><name sortKey="Horvath, A O" sort="Horvath, A O" uniqKey="Horvath A" first="A-O" last="Horvath">A-O Horvath</name><name sortKey="Lemogne, C" sort="Lemogne, C" uniqKey="Lemogne C" first="C" last="Lemogne">C. Lemogne</name><name sortKey="Slama, G" sort="Slama, G" uniqKey="Slama G" first="G" last="Slama">G. Slama</name><name sortKey="Sola Gazagnes, A" sort="Sola Gazagnes, A" uniqKey="Sola Gazagnes A" first="A" last="Sola-Gazagnes">A. Sola-Gazagnes</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Attale, C" sort="Attale, C" uniqKey="Attale C" first="C" last="Attale">C. Attale</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001816 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001816 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20934364
|texte= Therapeutic alliance and glycaemic control in type 1 diabetes: a pilot study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20934364" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |